These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 22369879

  • 1. Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo.
    Zalba S, Navarro I, Trocóniz IF, Tros de Ilarduya C, Garrido MJ.
    Eur J Pharm Biopharm; 2012 Jun; 81(2):273-80. PubMed ID: 22369879
    [Abstract] [Full Text] [Related]

  • 2. Development of a liposomal formulation of the natural flavonoid fisetin.
    Mignet N, Seguin J, Ramos Romano M, Brullé L, Touil YS, Scherman D, Bessodes M, Chabot GG.
    Int J Pharm; 2012 Feb 14; 423(1):69-76. PubMed ID: 21571054
    [Abstract] [Full Text] [Related]

  • 3. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H.
    J Control Release; 2009 Jul 01; 137(1):8-14. PubMed ID: 19285528
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.
    Chaudhury A, Das S, Lee RF, Tan KB, Ng WK, Tan RB, Chiu GN.
    Int J Pharm; 2012 Jul 01; 430(1-2):167-75. PubMed ID: 22537806
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure.
    Stark B, Pabst G, Prassl R.
    Eur J Pharm Sci; 2010 Nov 20; 41(3-4):546-55. PubMed ID: 20800680
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS, Matsumoto H, Doi Y, Nakamura H, Ishida T, Kiwada H.
    Eur J Pharm Biopharm; 2012 Aug 20; 81(3):524-31. PubMed ID: 22554766
    [Abstract] [Full Text] [Related]

  • 13. Amino acids as cryoprotectants for liposomal delivery systems.
    Mohammed AR, Coombes AG, Perrie Y.
    Eur J Pharm Sci; 2007 Apr 20; 30(5):406-13. PubMed ID: 17317117
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
    Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H.
    J Control Release; 2009 Feb 20; 134(1):18-25. PubMed ID: 19010364
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.